Abstract
Colorectal cancer is the second most common cause of cancer-related death in the United States. Twin studies suggest that 35% of all colorectal cancer cases are inherited. High-penetrance tumor susceptibility genes account for at most 3–6% of all colorectal cancer cases and the remainder of the unexplained risk is likely due to a combination of low to moderate penetrance genes. Recent genome-wide association studies have identified several SNPs near genes belonging to the transforming growth factor beta (TGF-β) superfamily such as GREM1 and SMAD7. Together with the recent discovery that constitutively decreased TGFBR1 expression is a potent modifier of colorectal cancer risk, these findings strongly suggest that germline variants of the TGF-β superfamily may account for a sizeable proportion of colorectal cancer cases. The TGF-β superfamily signaling pathways mediate many different biological processes during embryonic development, and in adult organisms they play a role in tissue homeostasis. TGF-β has a central role in inhibiting cell proliferation and also modulates processes such as cell invasion, immune regulation, and microenvironment modification. Mutations in the TGF-β type II receptor (TGFBR2) are estimated to occur in approximately 30% of colorectal carcinomas. Mutations in SMAD4 and BMPR1A are found in patients with familial juvenile polyposis, an autosomal dominant condition associated with an increased risk of colorectal cancer. This chapter provides an overview of the genetic basis of colorectal cancer and discusses recent discoveries related to alterations in the TGF-β pathways and their role in the development of colorectal cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA: A Cancer Journal for Clinicians, 59(4):225–249
Moertel C, Fleming TR, Macdonald JS, Mailliard JA (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Int Med 122:321–326
Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342
Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC (1994) A prospective study of family history and the risk of colorectal cancer. N Engl J Med 331:1669–1674
Johns LE, Houlston RS (2001) A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 96:2992–3003
Butterworth AS, Higgins JP, Pharoah P (2006) Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer 42:216–227
Lichtenstein P, Holm NV, Verkasalo PK et al (2000) Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85
Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J (1994) Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3:121–125
Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348:919–932
Laken SJ, Petersen GM, Gruber SB et al (1997) Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 17:79–83
Rozen P, Shomrat R, Strul H et al (1999) Prevalence of the I1307K APC gene variant in Israeli Jews of differing ethnic origin and risk for colorectal cancer. Gastroenterology 116:54–57
Rustgi AK (2007) The genetics of hereditary colon cancer. Genes Dev 21:2525–2538
Foulkes WD (2008) Inherited susceptibility to common cancers. N Engl J Med 359: 2143–2153
Lynch HT, Lynch JF, Lynch PM, Attard T (2008) Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. Fam Cancer 7:27–39
Al-Tassan N, Chmiel NH, Maynard J et al (2002) Inherited variants of MYH associated with somatic G:C–>T:A mutations in colorectal tumors. Nat Genet 30:227–232
Avezzu A, Agostini M, Pucciarelli S et al (2008) The role of MYH gene in genetic predisposition to colorectal cancer: another piece of the puzzle. Cancer Lett 268:308–313
Colebatch A, Hitchins M, Williams R, Meagher A, Hawkins NJ, Ward RL (2006) The role of MYH and microsatellite instability in the development of sporadic colorectal cancer. Br J Cancer 95:1239–1243
Croitoru ME, Cleary SP, Di Nicola N et al (2004) Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst 96:1631–1634
Enholm S, Hienonen T, Suomalainen A et al (2003) Proportion and phenotype of MYH-associated colorectal neoplasia in a population-based series of Finnish colorectal cancer patients. Am J Pathol 163:827–832
Kambara T, Whitehall VL, Spring KJ et al (2004) Role of inherited defects of MYH in the development of sporadic colorectal cancer. Genes Chromosomes Cancer 40:1–9
Wang L, Baudhuin LM, Boardman LA et al (2004) MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology 127:9–16
Zhou XL, Djureinovic T, Werelius B, Lindmark G, Sun XF, Lindblom A (2005) Germline mutations in the MYH gene in Swedish familial and sporadic colorectal cancer. Genet Test 9:147–151
Farrington SM, Tenesa A, Barnetson R et al (2005) Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Hum Genet 77:112–119
Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS (2009) Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 27:3975–3980
Lipton L, Halford SE, Johnson V et al (2003) Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway. Cancer Res 63:7595–7599
Poulsen ML, Bisgaard ML (2008) MUTYH associated polyposis (MAP). Curr Genomics 9:420–435
Kemp Z, Thirlwell C, Sieber O, Silver A, Tomlinson I (2004) An update on the genetics of colorectal cancer. Hum Mol Genet 13:R177–R185
Zanke BW, Greenwood CM, Rangrej J et al (2007) Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 39:989–994
Tomlinson I, Webb E, Carvajal-Carmona L et al (2007) A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 39:984–988
Jaeger E, Webb E, Howarth K et al (2008) Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nat Genet 40:26–28
Broderick P, Carvajal-Carmona L, Pittman AM et al (2007) A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet 39:1315–1317
Houlston RS, Webb E, Broderick P et al (2008) Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet 40:1426–1435
Tenesa A, Farrington SM, Prendergast JG et al (2008) Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet 40:631–637
Lee IM, Paffenbarger RS Jr (1992) Quetelet’s index and risk of colon cancer in college alumni. J Natl Cancer Inst 84:1326–1331
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638
Macinnis RJ, English DR, Hopper JL, Haydon AM, Gertig DM, Giles GG (2004) Body size and composition and colon cancer risk in men. Cancer Epidemiol Biomarkers Prev 13:553–559
Pischon T, Lahmann PH, Boeing H et al (2006) Body size and risk of colon and rectal cancer in the European prospective investigation into cancer and nutrition (EPIC). J Natl Cancer Inst 98:920–931
Larsson SC, Wolk A (2007) Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr 86:556–565
Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS (2005) Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97:1688–1694
Wei EK, Ma J, Pollak MN et al (2005) A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 14:850–855
Giovannucci E, Pollak MN, Platz EA et al (2000) A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9:345–349
Ma J, Giovannucci E, Pollak M et al (2004) A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 96:546–553
Sandhu MS, Dunger DB, Giovannucci EL (2002) Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 94:972–980
Kaklamani VG, Sadim M, Hsi A et al (2008) Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res 68:3178–3184
Carvajal-Carmona LG, Spain S, The CORGI Consortium et al (2009) Common variation at the adiponectin locus is not associated with colorectal cancer risk in the UK. Hum Mol Genet 18:1889–1892
Noffsinger AE (2009) Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol 4:343–364
Castells A (2008) MYH-associated polyposis: adenomas and hyperplastic polyps, partners in crime? Gastroenterology 135:1857–1859
Wynter CV, Walsh MD, Higuchi T, Leggett BA, Young J, Jass JR (2004) Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer. Gut 53:573–580
Nagasaka T, Sasamoto H, Notohara K et al (2004) Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 22:4584–4594
Kumar K, Brim H, Giardiello F et al (2009) Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clin Cancer Res 15:1155–1161
Samowitz WS, Albertsen H, Sweeney C et al (2006) Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 98:1731–1738
Ajioka Y, Watanabe H, Jass JR, Yokota Y, Kobayashi M, Nishikura K (1998) Infrequent K-ras codon 12 mutation in serrated adenomas of human colorectum. Gut 42:680–684
Sawyer EJ, Hanby AM, Rowan AJ et al (2002) The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. J Pathol 196:437–444
O‘Brien MJ, Yang S, Mack C et al (2006) Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol 30:1491–1501
O‘Brien MJ, Yang S, Clebanoff JL et al (2004) Hyperplastic (serrated) polyps of the colorectum: relationship of CpG island methylator phenotype and K-ras mutation to location and histologic subtype. Am J Surg Pathol 28:423–434
Yang S, Farraye FA, Mack C, Posnik O, O‘Brien MJ (2004) BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol 28:1452–1459
Jass JR, Baker K, Zlobec I et al (2006) Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer. Histopathology 49:121–131
Chan TL, Zhao W, Leung SY, Yuen ST (2003) BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 63:4878–4881
Spring KJ, Zhao ZZ, Karamatic R et al (2006) High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 131:1400–1407
Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934
Brosens LAA, van Hattem A, Hylind LM et al (2007) Risk of colorectal cancer in juvenile polyposis. Gut 56:965–967
Howe JR, Ringold JC, Summers RW, Mitros FA, Nishimura DY, Stone EM (1998) A gene for familial juvenile polyposis maps to chromosome 18q21.1. Am J Hum Genet 62:1129–1136
Howe JR, Roth S, Ringold JC et al (1998) Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 280:1086–1088
Sweet K, Willis J, Zhou XP et al (2005) Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 294:2465–2473
Howe JR, Haidle JL, Lal G et al (2007) ENG mutations in MADH4/BMPR1A mutation negative patients with juvenile polyposis. Clin Genet 71:91–92
Grady WM, Carethers JM (2008) Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135:1079–1099
Massague J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103:295–309
Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685–700
Goumans MJ, Valdimarsdottir G, Itoh S et al (2003) Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGF[beta]/ALK5 signaling. Mol Cell 12:817–828
Imamura T, Takase M, Nishihara A et al (1997) Smad6 inhibits signalling by the tgf-beta superfamily. Nature 389:622–626
Ebisawa T, Fukuchi M, Murakami G et al (2001) Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 276:12477–12480
Shi W, Sun C, He B et al (2004) GADD34-PP1c recruited by Smad7 dephosphorylates TGFbeta type I receptor. J Cell Biol 164:291–300
Massague J (1998) TGF-beta signal transduction. Annu Rev Biochem 67:753–791
Massague J (2008) TGFbeta in Cancer. Cell 134:215–230
Kim YS, Yi YS, Choi SG, Kim SJ (1999) Development of TGF-beta resistance during malignant progression [review]. Arch Pharm Res 22:1–8
Grady WM, Myeroff LL, Swinler SE et al (1999) Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 59: 320–324
Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29:117–129
Bhowmick NA, Chytil A, Plieth D et al (2004) TGF-{beta} signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:848–851
Cheng N, Chytil A, Shyr Y, Joly A, Moses HL (2008) Transforming growth factor-{beta} signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res 6:1521–1533
Maggio-Price L, Treuting P, Zeng W, Tsang M, Bielefeldt-Ohmann H, Iritani BM (2006) Helicobacter infection is required for inflammation and colon cancer in Smad3-deficient mice. Cancer Res 66:828–838
Kim BG, Li C, Qiao W et al (2006) Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 441:1015–1019
Shipitsin M, Campbell LL, Argani P et al (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11:259–273
Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15:740–746
Derynck R, Akhurst RJ (2007) Differentiation plasticity regulated by TGF-[beta] family proteins in development and disease. Nat Cell Biol 9:1000–1004
Mani SA, Guo W, Liao MJ et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715
Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A (2006) Transforming growth factor-{beta} employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 174:175–183
Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, Moustakas A (2008) HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem 283:33437–33446
Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL (2005) Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 307:1603–1609
Seton-Rogers SE, Lu Y, Hines LM et al (2004) Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc Natl Acad Sci USA 101:1257–1262
Grady WM, Markowitz SD (2002) Genetic and epigenetic alterations in colon cancer. Annu Rev Genom Hum Genet 3:101–128
Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y (2006) Colorectal cancer: genetics of development and metastasis. J Gastroenterol 41:185–192
Parsons R, Myeroff LL, Liu B et al (1995) Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 55:5548–5550
Ilyas M, Efstathiou JA, Straub J, Kim HC, Bodmer WF (1999) Transforming growth factor beta stimulation of colorectal cancer cell lines: type II receptor bypass and changes in adhesion molecule expression. Proc Natl Acad Sci USA 96:3087–3091
Grady WM, Willis JE, Trobridge P et al (2006) Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations. Int J Cancer 118:600–608
Watanabe T, Wu TT, Catalano PJ et al (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196–1206
Samowitz WS, Curtin K, Leppert MF, Slattery ML (2002) The prognostic implications of BAX and TGF[BETA]RII mutations in colon cancers with microsatellite instability. Mod Pathol 15:143A
Samowitz WS, Curtin K, Neuhausen S, Schaffer D, Slattery ML (2002) Prognostic implications of BAX and TGFBRII mutations in colon cancers with microsatellite instability. Genes Chromosomes Cancer 35:368–371
Ku JL, Park SH, Yoon KA et al (2007) Genetic alterations of the TGF-beta signaling pathway in colorectal cancer cell lines: a novel mutation in Smad3 associated with the inactivation of TGF-beta-induced transcriptional activation. Cancer Lett 247:283–292
Kaklamani VG, Hou N Bian Y et al (2003) TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol 21:3236–3243
Pasche B, Kaklamani VG, Hou N et al (2004) TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. J Clin Oncol 22:756–758
Zhang HT, Zhao J, Zheng SY, Chen XF (2005) Is TGFBR1*6A really associated with increased risk of cancer? J Clin Oncol 23:7743–7744
Liao RY, Mao C, Qiu LX, Ding H, Chen Q, Pan HF (2009) TGFBR1*6A/9A polymorphism and cancer risk: a meta-analysis of 13,662 cases and 14,147 controls. Mol Biol Rep (published online November 1, 2009)
Pasche B, Knobloch TJ, Bian Y et al (2005) Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA 294:1634–1646
Bian Y, Knobloch TJ, Sadim M et al (2007) Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon cancer development. Hum Mol Genet 16:3128–3135
Rosman DS, Phukan S, Huang CC, Pasche B (2008) TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through RhoA activation. Cancer Res 68: 1319–1328
Zeng Q, Phukan S, Xu Y et al (2009) Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development. Cancer Res 69:678–686
Valle L, Serena-Acedo T, Liyanarachchi S et al (2008) Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science 321:1361–1365
Thiagalingam S, Lengauer C, Leach FS et al (1996) Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 13:343–346
Takagi Y, Kohmura H, Futamura M et al (1996) Somatic alterations of the dpc4 gene in human colorectal cancers in vivo. Gastroenterology 111:1369–1372
Ando T, Sugai T, Habano W, Jiao YF, Suzuki K (2005) Analysis of SMAD4/DPC4 gene alterations in multiploid colorectal carcinomas. J Gastroenterol 40:708–715
Salovaara R, Roth S, Loukola A et al (2002) Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut 51:56–59
Eppert K, Scherer SW, Ozcelik H et al (1996) Madr2 maps to 18q21 and encodes a tgfbeta-regulated mad-related protein that is functionally mutated in colorectal carcinoma. Cell 86:543–552
Yang X, Li CL, Xu XL, Deng CX (1998) The tumor suppressor smad4/dpc4 is essential for epiblast proliferation and mesoderm induction in mice. Proc Natl Acad Sci USA 95: 3667–3672
Weinstein M, Yang X, Deng C (2000) Functions of mammalian Smad genes as revealed by targeted gene disruption in mice. Cytokine Growth Factor Rev 11:49–58
Mishra L, Shetty K, Tang Y, Stuart A, Byers SW (2005) The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 24:5775–5789
Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM (1998) Intestinal tumorigenesis in compound mutant mice of both dpc4 (Smad4) and apc genes. Cell 92:645–656
Kitamura T, Kometani K, Hashida H et al (2007) SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet 39:467–475
Maitra A, Krueger JE, Tascilar M et al (2000) Carcinoid tumors of the extrahepatic bile ducts: a study of seven cases. Am J Surg Pathol 24:1501–1510
Isaksson-Mettavainio M, Palmqvist R, Forssell J, Stenling R, Oberg A (2006) SMAD4/DPC4 expression and prognosis in human colorectal cancer. Anticancer Res 26:507–510
Alazzouzi H, Alhopuro P, Salovaara R et al (2005) SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 11:2606–2611
Boulay JL, Mild G, Lowy A et al (2002) SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. Br J Cancer 87:630–634
Sjoblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274
Zhu YA, Richardson JA, Parada LF, Graff JM (1998) Smad3 mutant mice develop metastatic colorectal cancer. Cell 94:703–714
Sodir NM, Chen X, Park Ret al (2006) Smad3 deficiency promotes tumorigenesis in the distal colon of ApcMin/+ mice. Cancer Res 66:8430–8438
Datto MB, Frederick JP, Pan LH, Borton AJ, Zhuang Y, Wang XF (1999) Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol Cell Biol 19:2495–2504
Yang X, Letterio JJ, Lechleider RJ et al (1999) Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 18:1280–1291
Maggio-Price L, Treuting P, Bielefeldt-Ohmann H et al (2009) Bacterial infection of Smad3/Rag2 double-null mice with transforming growth factor-beta dysregulation as a model for studying inflammation-associated colon cancer. Am J Pathol 174:317–329
He XC, Zhang J, Tong WG et al (2004) BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-[beta]-catenin signaling. Nat Genet 36:1117–1121
Hardwick JC, Kodach LL, Offerhaus GJ, van den Brink GR (2008) Bone morphogenetic protein signalling in colorectal cancer. Nat Rev Cancer 8:806–812
Loh K, Chia JA, Greco S et al (2008) Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development. Genes Chromosomes Cancer 47:449–460
Motoyama K, Tanaka F, Kosaka Y et al (2008) Clinical significance of BMP7 in human colorectal cancer. Ann Surg Oncol 15:1530–1537
Deng H, Ravikumar TS, Yang WL (2009) Overexpression of bone morphogenetic protein 4 enhances the invasiveness of Smad4-deficient human colorectal cancer cells. Cancer Lett 281:220–231
Kodach LL, Wiercinska E, de Miranda NF et al (2008) The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology 134:1332–1341
Kodach LL, Wiercinska E, de Miranda NF et al (2008) The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology 134:1332–1341
Massague J, Seoane J, Wotton D (2005) Smad transcription factors. Genes Dev 19:2783–2810
Cerutti JM, Ebina KN, Matsuo SE, Martins L, Maciel RM, Kimura ET (2003) Expression of Smad4 and Smad7 in human thyroid follicular carcinoma cell lines. J Endocrinol Invest 26:516–521
Dowdy SC, Mariani A, Reinholz MM et al (2005) Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer. Gynecol Oncol 96:368–373
Zhu Q, Krakowski AR, Dunham EE et al (2007) Dual role of SnoN in mammalian tumorigenesis. Mol Cell Biol 27:324–339
Acknowledgments
This work is supported by grants R01 CA108741, R01 CA112520, R01 137000, and P60 AR048098 from NIH.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Bellam, N., Pasche, B. (2010). TGF-β Signaling Alterations and Colon Cancer. In: Pasche, B. (eds) Cancer Genetics. Cancer Treatment and Research, vol 155. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-6033-7_5
Download citation
DOI: https://doi.org/10.1007/978-1-4419-6033-7_5
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-6032-0
Online ISBN: 978-1-4419-6033-7
eBook Packages: MedicineMedicine (R0)